Brief: Cspc Pharmaceutical Initiates Phase I/II Trial Of SYS6052 Herpes Zoster Vaccine In China
BRIEF-Cspc Pharmaceutical Initiates Phase I/II Trial Of SYS6052 Herpes Zoster Vaccine In China Nov 2 (Reuters) - CSPC PHARMACEUTICAL GROUP LIMITED 1093.HK:
CO INITIATES PHASE I/II TRIAL OF SYS6052 HERPES ZOSTER VACCINE IN CHINA
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Initiates Phase I Clinical Trial Of SYS6057 RSV Vaccine In China
Brief: Cspc Pharmaceutical Initiates Phase I/II Trial Of SYS6052 Herpes Zoster Vaccine In China
Brief: CSPC Pharmaceutical - Phase III Trial Of Prusogliptin, Dapagliflozin, Metformin Achieves Positive Topline Results
Brief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer